Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Two-Drug pain block ease recovery after colon cancer surgery?

NCT ID NCT06370949

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial compares two approaches to a nerve block (TAP block) for pain after colorectal cancer surgery. One group receives the standard numbing drug bupivacaine, while the other gets bupivacaine plus dexmedetomidine, a drug that may extend pain relief. The study measures pain scores using a 0–10 scale in the hours after surgery. About 84 adults with colorectal cancer scheduled for surgery are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine and dexmedetomidine
What this could lead to
If it works, this could offer better pain relief after colorectal cancer surgery, reducing the need for strong painkillers.
What could go wrong
This is a small, early-stage trial. The added drug may not improve pain control and could cause side effects like low blood pressure or drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

84 people

The number who actually took part.

Started

May 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators will evaluate colorectal cancer patients from Ankara Dr. Abdurrahman Yurtaslan Oncology Train and Research Hospital who will undergo colorectal cancer surgery. The investigators will exclude patients who no longer want to participate at any part of the trial. A total of 84 patients' data will be collected.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * colorectal cancer diagnosis * undergoing colorectal cancer surgery Exclusion Criteria: * allergic reaction to local anesthetics * bleeding anomalies * infection in TAP block area

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital

    Ankara, Cankaya, 06110, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.